Ferroptosis, pyroptosis and necroptosis in hepatocellular carcinoma immunotherapy: Mechanisms and immunologic landscape (Review)
International Journal of Oncology · 2024
DOI: 10.3892/ijo.2024.5651 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Oncology, 2024. Verfasst von Rui-Jia Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, P.R. China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Pyroptosis, Ferroptosis. Die Arbeit wurde bisher 19-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC), one of the leading causes of cancer‑related mortality worldwide, is challenging to identify in its early stages and prone to metastasis, and the prognosis of patients with this disease is poor. Treatment options for HCC are limited, with even radical treatments being associated with a risk of recurrence or transformation in the short term. Furthermore, the multi‑tyrosine kinase inhibitors approved for first‑line therapy have marked drawbacks, including drug resistance and side effects. The rise and breakthrough of immune checkpoint inhibitors (ICIs) have provided a novel direction for HCC immunotherapy but these have the drawback of low response rates. Since avoiding apoptosis is a universal feature of cancer, the induction of non‑apoptotic regulatory cell death (NARCD) is a novel strategy for HCC immunotherapy. At present, NARCD pathways, including ferroptosis, pyroptosis and necroptosis, are novel potential forms of immunogenic cell death, which have synergistic effects with antitumor immunity, transforming immune 'cold' tumors into immune 'hot' tumors and exerting antitumor effects. Therefore, these pathways may be targeted as a novel treatment strategy for HCC. In the present review, the roles of ferroptosis, pyroptosis and necroptosis in antitumor immunity in HCC are discussed, and the relevant targets and signaling pathways, and the current status of combined therapy with ICIs are summarized. The prospects of targeting ferroptosis, pyroptosis and necroptosis in HCC immunotherapy are also considered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, P.R. China.
- Guang'anmen Hospital, Chinese Academy of Traditional Chinese Medicine, Beijing 100053, P.R. China.
Zitieren
APA
Liu, R. J., Yu, X. D., Yan, S. S., Guo, Z. W., Zao, X. B., & Zhang, Y. S. (2024). Ferroptosis, pyroptosis and necroptosis in hepatocellular carcinoma immunotherapy: Mechanisms and immunologic landscape (Review). International Journal of Oncology. https://doi.org/10.3892/ijo.2024.5651
Vancouver
Liu RJ, Yu XD, Yan SS, Guo ZW, Zao XB, Zhang YS. Ferroptosis, pyroptosis and necroptosis in hepatocellular carcinoma immunotherapy: Mechanisms and immunologic landscape (Review). International Journal of Oncology. 2024. doi:10.3892/ijo.2024.5651
BibTeX
@article{Liu2024,
author = {Liu, Rui-Jia and Yu, Xu-Dong and Yan, Shao-Shuai and Guo, Zi-Wei and Zao, Xiao-Bin and Zhang, Yao-Sheng},
title = {Ferroptosis, pyroptosis and necroptosis in hepatocellular carcinoma immunotherapy: Mechanisms and immunologic landscape (Review)},
journal = {International Journal of Oncology},
year = {2024},
doi = {10.3892/ijo.2024.5651}
}
EUVIMED